Manufacturing of hybrid drug delivery systems by utilizing the fused filament fabrication (FFF) technology

Research output: Contribution to journalEditorialResearchpeer-review

Standard

Manufacturing of hybrid drug delivery systems by utilizing the fused filament fabrication (FFF) technology. / Eleftheriadis, Georgios K.; Katsiotis, Christos S.; Genina, Natalja; Boetker, Johan; Rantanen, Jukka; Fatouros, Dimitrios G.

In: Expert Opinion on Drug Delivery, Vol. 17, No. 8, 2020, p. 1063-1067.

Research output: Contribution to journalEditorialResearchpeer-review

Harvard

Eleftheriadis, GK, Katsiotis, CS, Genina, N, Boetker, J, Rantanen, J & Fatouros, DG 2020, 'Manufacturing of hybrid drug delivery systems by utilizing the fused filament fabrication (FFF) technology', Expert Opinion on Drug Delivery, vol. 17, no. 8, pp. 1063-1067. https://doi.org/10.1080/17425247.2020.1776260

APA

Eleftheriadis, G. K., Katsiotis, C. S., Genina, N., Boetker, J., Rantanen, J., & Fatouros, D. G. (2020). Manufacturing of hybrid drug delivery systems by utilizing the fused filament fabrication (FFF) technology. Expert Opinion on Drug Delivery, 17(8), 1063-1067. https://doi.org/10.1080/17425247.2020.1776260

Vancouver

Eleftheriadis GK, Katsiotis CS, Genina N, Boetker J, Rantanen J, Fatouros DG. Manufacturing of hybrid drug delivery systems by utilizing the fused filament fabrication (FFF) technology. Expert Opinion on Drug Delivery. 2020;17(8):1063-1067. https://doi.org/10.1080/17425247.2020.1776260

Author

Eleftheriadis, Georgios K. ; Katsiotis, Christos S. ; Genina, Natalja ; Boetker, Johan ; Rantanen, Jukka ; Fatouros, Dimitrios G. / Manufacturing of hybrid drug delivery systems by utilizing the fused filament fabrication (FFF) technology. In: Expert Opinion on Drug Delivery. 2020 ; Vol. 17, No. 8. pp. 1063-1067.

Bibtex

@article{22acf8100b3a4ce990815465e9ae1524,
title = "Manufacturing of hybrid drug delivery systems by utilizing the fused filament fabrication (FFF) technology",
abstract = "The potential of fused filament fabrication (FFF) for the administration of active pharmaceutical compounds is a recent approach to develop complex and custom-made drug delivery systems (DDSs). However, the FFF technology is characterized by certain limitations, which are associated with the nature of the process, i.e., the required mechanical properties of the feedstock, as well as the thermal stability of the incorporated polymers, excipients and active compounds. Thus, hybrid DDSs have been recently introduced, to overcome these boundaries. The concept of these systems is defined by the effective coupling of FFF with conventional manufacturing technologies, as a novel pathway to expand the available pool of raw materials and pharmaceutical applications of FFF.",
keywords = "3D printing, automated filling, biologics, electrospinning, fused filament fabrication, hybrid systems, injection molding, inkjet printing",
author = "Eleftheriadis, {Georgios K.} and Katsiotis, {Christos S.} and Natalja Genina and Johan Boetker and Jukka Rantanen and Fatouros, {Dimitrios G.}",
year = "2020",
doi = "10.1080/17425247.2020.1776260",
language = "English",
volume = "17",
pages = "1063--1067",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Taylor & Francis",
number = "8",

}

RIS

TY - JOUR

T1 - Manufacturing of hybrid drug delivery systems by utilizing the fused filament fabrication (FFF) technology

AU - Eleftheriadis, Georgios K.

AU - Katsiotis, Christos S.

AU - Genina, Natalja

AU - Boetker, Johan

AU - Rantanen, Jukka

AU - Fatouros, Dimitrios G.

PY - 2020

Y1 - 2020

N2 - The potential of fused filament fabrication (FFF) for the administration of active pharmaceutical compounds is a recent approach to develop complex and custom-made drug delivery systems (DDSs). However, the FFF technology is characterized by certain limitations, which are associated with the nature of the process, i.e., the required mechanical properties of the feedstock, as well as the thermal stability of the incorporated polymers, excipients and active compounds. Thus, hybrid DDSs have been recently introduced, to overcome these boundaries. The concept of these systems is defined by the effective coupling of FFF with conventional manufacturing technologies, as a novel pathway to expand the available pool of raw materials and pharmaceutical applications of FFF.

AB - The potential of fused filament fabrication (FFF) for the administration of active pharmaceutical compounds is a recent approach to develop complex and custom-made drug delivery systems (DDSs). However, the FFF technology is characterized by certain limitations, which are associated with the nature of the process, i.e., the required mechanical properties of the feedstock, as well as the thermal stability of the incorporated polymers, excipients and active compounds. Thus, hybrid DDSs have been recently introduced, to overcome these boundaries. The concept of these systems is defined by the effective coupling of FFF with conventional manufacturing technologies, as a novel pathway to expand the available pool of raw materials and pharmaceutical applications of FFF.

KW - 3D printing

KW - automated filling

KW - biologics

KW - electrospinning

KW - fused filament fabrication

KW - hybrid systems

KW - injection molding

KW - inkjet printing

U2 - 10.1080/17425247.2020.1776260

DO - 10.1080/17425247.2020.1776260

M3 - Editorial

C2 - 32511025

AN - SCOPUS:85087136750

VL - 17

SP - 1063

EP - 1067

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 8

ER -

ID: 244325540